Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Chronic Over-expression of Fibroblast Growth Factor 21 Increases Bile Acid Biosynthesis by Opposing FGF15/19 Action.

Zhang J, Gupte J, Gong Y, Weiszmann J, Zhang Y, Lee KJ, Richards WG, Li Y.

EBioMedicine. 2017 Feb;15:173-183. doi: 10.1016/j.ebiom.2016.12.016. Epub 2016 Dec 24.

2.

In Vitro and in Vivo Analyses Reveal Profound Effects of Fibroblast Growth Factor 16 as a Metabolic Regulator.

Rulifson IC, Collins P, Miao L, Nojima D, Lee KJ, Hardy M, Gupte J, Hensley K, Samayoa K, Cam C, Rottman JB, Ollmann M, Richards WG, Li Y.

J Biol Chem. 2017 Feb 3;292(5):1951-1969. doi: 10.1074/jbc.M116.751404. Epub 2016 Dec 23.

3.

Soluble CLEC2 Extracellular Domain Improves Glucose and Lipid Homeostasis by Regulating Liver Kupffer Cell Polarization.

Wu X, Zhang J, Ge H, Gupte J, Baribault H, Lee KJ, Lemon B, Coberly S, Gong Y, Pan Z, Rulifson IC, Gardner J, Richards WG, Li Y.

EBioMedicine. 2015 Feb 25;2(3):214-24. doi: 10.1016/j.ebiom.2015.02.013. eCollection 2015 Mar.

4.

Trefoil Factor 3 (TFF3) Is Regulated by Food Intake, Improves Glucose Tolerance and Induces Mucinous Metaplasia.

Ge H, Gardner J, Wu X, Rulifson I, Wang J, Xiong Y, Ye J, Belouski E, Cao P, Tang J, Lee KJ, Coberly S, Wu X, Gupte J, Miao L, Yang L, Nguyen N, Shan B, Yeh WC, Véniant MM, Li Y, Baribault H.

PLoS One. 2015 Jun 17;10(6):e0126924. doi: 10.1371/journal.pone.0126924. eCollection 2015.

5.

Advancing therapeutic discovery through phenotypic screening of the extracellular proteome using hydrodynamic intravascular injection.

Baribault H, Majeti JZ, Ge H, Wang J, Xiong Y, Gardner J, Yang L, Gupte J, Gong Y, Pan Z, Cutler G, Kassner P, Tu H, Shan B, Wu X, Li Y.

Expert Opin Ther Targets. 2014 Nov;18(11):1253-64. doi: 10.1517/14728222.2014.968128. Epub 2014 Oct 7.

PMID:
25287216
6.

Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions.

Ge H, Zhang J, Gong Y, Gupte J, Ye J, Weiszmann J, Samayoa K, Coberly S, Gardner J, Wang H, Corbin T, Chui D, Baribault H, Li Y.

J Biol Chem. 2014 Oct 31;289(44):30470-80. doi: 10.1074/jbc.M114.592022. Epub 2014 Sep 9.

7.

FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein.

Smith R, Duguay A, Bakker A, Li P, Weiszmann J, Thomas MR, Alba BM, Wu X, Gupte J, Yang L, Stevens J, Hamburger A, Smith S, Chen J, Komorowski R, Moore KW, Véniant MM, Li Y.

PLoS One. 2013 Apr 22;8(4):e61432. doi: 10.1371/journal.pone.0061432. Print 2013.

8.

A novel approach to improve the function of FGF21.

Smith R, Duguay A, Weiszmann J, Stanislaus S, Belouski E, Cai L, Yie J, Xu J, Gupte J, Wu X, Li Y.

BioDrugs. 2013 Apr;27(2):159-66. doi: 10.1007/s40259-013-0013-x.

PMID:
23456652
9.

Dual actions of fibroblast growth factor 19 on lipid metabolism.

Wu X, Ge H, Baribault H, Gupte J, Weiszmann J, Lemon B, Gardner J, Fordstrom P, Tang J, Zhou M, Wang M, Li Y.

J Lipid Res. 2013 Feb;54(2):325-32. doi: 10.1194/jlr.M027094. Epub 2012 Dec 2.

10.

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.

Foltz IN, Hu S, King C, Wu X, Yang C, Wang W, Weiszmann J, Stevens J, Chen JS, Nuanmanee N, Gupte J, Komorowski R, Sekirov L, Hager T, Arora T, Ge H, Baribault H, Wang F, Sheng J, Karow M, Wang M, Luo Y, McKeehan W, Wang Z, Véniant MM, Li Y.

Sci Transl Med. 2012 Nov 28;4(162):162ra153. doi: 10.1126/scitranslmed.3004690.

11.

Signaling property study of adhesion G-protein-coupled receptors.

Gupte J, Swaminath G, Danao J, Tian H, Li Y, Wu X.

FEBS Lett. 2012 Apr 24;586(8):1214-9. doi: 10.1016/j.febslet.2012.03.014. Epub 2012 Mar 21.

12.

Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism.

Ge H, Baribault H, Vonderfecht S, Lemon B, Weiszmann J, Gardner J, Lee KJ, Gupte J, Mookherjee P, Wang M, Sheng J, Wu X, Li Y.

PLoS One. 2012;7(3):e33603. doi: 10.1371/journal.pone.0033603. Epub 2012 Mar 23.

13.

A unique FGF23 with the ability to activate FGFR signaling through both αKlotho and βKlotho.

Wu X, Weiszmann J, Ge H, Baribault H, Stevens J, Hawkins N, Vonderfecht S, Gardner J, Gupte J, Sheng J, Wang M, Li Y.

J Mol Biol. 2012 Apr 20;418(1-2):82-9. doi: 10.1016/j.jmb.2012.02.027. Epub 2012 Feb 24.

PMID:
22370560
14.

The FGFR D3 domain determines receptor selectivity for fibroblast growth factor 21.

Gupte J, Yang L, Wu X, Weiszmann J, Hecht R, Lemon B, Lindberg R, Wang Z, Li Y.

J Mol Biol. 2011 May 6;408(3):491-502. doi: 10.1016/j.jmb.2011.03.003. Epub 2011 Mar 23.

PMID:
21392510
15.

Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).

Wu X, Ge H, Lemon B, Vonderfecht S, Baribault H, Weiszmann J, Gupte J, Gardner J, Lindberg R, Wang Z, Li Y.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14158-63. doi: 10.1073/pnas.1009427107. Epub 2010 Jul 26.

16.

FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.

Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, Li Y.

J Biol Chem. 2010 Feb 19;285(8):5165-70. doi: 10.1074/jbc.M109.068783. Epub 2009 Dec 15.

17.

Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.

Wu X, Ge H, Lemon B, Weiszmann J, Gupte J, Hawkins N, Li X, Tang J, Lindberg R, Li Y.

Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14379-84. doi: 10.1073/pnas.0907812106. Epub 2009 Aug 12.

18.

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182.

19.

C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors.

Wu X, Lemon B, Li X, Gupte J, Weiszmann J, Stevens J, Hawkins N, Shen W, Lindberg R, Chen JL, Tian H, Li Y.

J Biol Chem. 2008 Nov 28;283(48):33304-9. doi: 10.1074/jbc.M803319200. Epub 2008 Oct 1.

20.

Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years.

Flynn JT, Meyers KE, Neto JP, de Paula Meneses R, Zurowska A, Bagga A, Mattheyse L, Shi V, Gupte J, Solar-Yohay S, Han G; Pediatric Valsartan Study Group.

Hypertension. 2008 Aug;52(2):222-8. doi: 10.1161/HYPERTENSIONAHA.108.111054. Epub 2008 Jun 30.

PMID:
18591457
21.

Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.

Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Gupte J, Staikos L, Hua TA, Shi V, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M; Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension Investigators.

Blood Press. 2008;17(1):7-17. doi: 10.1080/08037050801972857.

PMID:
18568687
22.

Elucidation of signaling and functional activities of an orphan GPCR, GPR81.

Ge H, Weiszmann J, Reagan JD, Gupte J, Baribault H, Gyuris T, Chen JL, Tian H, Li Y.

J Lipid Res. 2008 Apr;49(4):797-803. doi: 10.1194/jlr.M700513-JLR200. Epub 2008 Jan 3.

23.

Co-receptor requirements for fibroblast growth factor-19 signaling.

Wu X, Ge H, Gupte J, Weiszmann J, Shimamoto G, Stevens J, Hawkins N, Lemon B, Shen W, Xu J, Veniant MM, Li YS, Lindberg R, Chen JL, Tian H, Li Y.

J Biol Chem. 2007 Oct 5;282(40):29069-72. Epub 2007 Aug 21.

24.

Exceptional early blood pressure control rates: the ACCOMPLISH trial.

Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M; ACCOMPLISH Investigators.

Blood Press. 2007;16(2):80-6.

PMID:
17612905
25.

Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.

Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K.

Blood Press. 2007;16(1):13-9.

PMID:
17453747
26.

The G-protein-coupled receptor GPR103 regulates bone formation.

Baribault H, Danao J, Gupte J, Yang L, Sun B, Richards W, Tian H.

Mol Cell Biol. 2006 Jan;26(2):709-17.

27.

Elucidation of signaling properties of vasopressin receptor-related receptor 1 by using the chimeric receptor approach.

Gupte J, Cutler G, Chen JL, Tian H.

Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1508-13. Epub 2004 Feb 2.

28.

A candidate prostate cancer susceptibility gene at chromosome 17p.

Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA.

Nat Genet. 2001 Feb;27(2):172-80.

PMID:
11175785
29.

BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines.

Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendricks K, Ghaffari S, Iliev D, Penn B, Woodland AM, Smith R, Salada G, Carillo A, Laity K, Gupte J, Swedlund B, Tavtigian SV, Teng DH, Lees E.

Cancer Res. 2000 Nov 1;60(21):6171-7.

30.

Genomic structure, chromosomal location, and mutation analysis of the human CDC14A gene.

Wong AK, Chen Y, Lian L, Ha PC, Petersen K, Laity K, Carillo A, Emerson M, Heichman K, Gupte J, Tavtigian SV, Teng DH.

Genomics. 1999 Jul 15;59(2):248-51.

PMID:
10409437
31.

BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing.

Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Thomas A, et al.

JAMA. 1997 Oct 15;278(15):1242-50.

PMID:
9333265
32.

Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.

Jacobus NV, Immermann FW, Gupte JM, Testa RT.

Clin Infect Dis. 1993 Jun;16 Suppl 4:S344-8. No abstract available.

PMID:
8391862
33.

Mild radioiodination of insulin with dichloramine-T.

Jyotsna T, Pillai MR, Gupte JH, Mani RS.

Int J Rad Appl Instrum B. 1986;13(5):549-50.

PMID:
3546211
34.

Carbodiimide used in coupling triiodothyronine antibody to carboxymethyl-cellulose powder for solid-phase radioimmunoassay.

Jyotsna J, Pillai MR, Gupte JH, Mani RS.

Clin Chem. 1986 Jan;32(1 Pt 1):229. No abstract available.

35.

Fixation of sulphur in the gut by bismuth salts.

Wright JT, Gupte J.

Gut. 1964 Oct;5(5):467-72. No abstract available.

Supplemental Content

Support Center